First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Toshio ShimizuJacob M SandsKiyotaka YohAlexander I SpiraEdward B GaronSatoru KitazonoMelissa Lynne JohnsonFunda Meric-BernstamAnthony W TolcherNoboru YamamotoJon GreenbergYui KawasakiHong Zebger-GongFumiaki KobayashiPenny PhillipsAaron E LisbergRebecca S HeistPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Promising antitumor activity and a manageable safety profile were seen with Dato-DXd in heavily pretreated patients with advanced NSCLC. Further investigation as first-line combination therapy in advanced NSCLC and as monotherapy in the second-line setting and beyond is ongoing.